The use of GLP‐1 and SGLT‐2 inhibitors which have both been shown to cause weight loss, improve survival and potentially stabilize eGFR is preferable over insulin in our view, and we reserve insulin as back‐up therapy after initiation of these agents in those with NASH cirrhosis. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.